novo nordisk glp-1 patent litigation Compounding Crackdown Novo's GLP-1 Patent Suit Against

Patients with a first-degree relative (parent, sibling, or child) diagnosed with MTC or MEN 2 should inform their healthcare provider before starting GLP-1 medications

With the ongoing obesity epidemic 1,2 and the emergence of promising new pharmacologic agents for obesity such as GLP-1 agonists, 3 providers may be increasingly called upon to consider incorporating weight-loss pharmacotherapy into clinical practice

The 1mg group lost nearly 10% of their body weight but still 50% dropped out

While emerging research suggests gut bacteria may influence metabolic health, the evidence supporting probiotics for meaningful weight loss remains limited and preliminary

Patient Experience Many community members have successfully achieved their weight loss goals through our program

How do I handle food aversions on GLP-1